创新药阈值及其医保支付模式探讨

孙利华; 李世琪; 范嘉宁

doi:10.19546/j.issn.1674-3830.2022.8.009

中国医疗保险 ›› 2022, Vol. 0 ›› Issue (8) : 53-55. DOI: 10.19546/j.issn.1674-3830.2022.8.009

观察思考

创新药阈值及其医保支付模式探讨

孙利华, 李世琪, 范嘉宁

作者信息 +

Discussion on the Threshold of Innovative Drugs and Their Medical Insurance Payment Model

Author information +

文章历史 +

摘要

绝大多数创新药的ICER值都高于阈值,而“一刀切”地提高其医保准入阈值并不利于激励增量价值高的创新药物研发。应当对创新药进行细分并区别施策,对医保基金无法持续承受,但相较于同类药增量价值较高的创新药,可以由医保和患者共同分担药品费用。

Abstract

The ICER value of the vast majority of innovative drugs is higher than the threshold, and raising the threshold of medical insurance access indiscriminately is not conducive to stimulating the research and development of innovative drugs with high incremental value. Innovative drugs should be subdivided and policies should be differentiated. Some drugs cannot be sustained by medical insurance funds, however, compared with of similar drugs, they have higher incremental value, as a result, medical insurance and patients can share the drug costs.

导出引用

孙利华, 李世琪, 范嘉宁. 创新药阈值及其医保支付模式探讨[J]. 中国医疗保险. 2022, 0(8): 53-55 https://doi.org/10.19546/j.issn.1674-3830.2022.8.009

Discussion on the Threshold of Innovative Drugs and Their Medical Insurance Payment Model[J]. China Health Insurance. 2022, 0(8): 53-55 https://doi.org/10.19546/j.issn.1674-3830.2022.8.009

中图分类号： F840.684 C913.7

参考文献

[1] 孙利华. 药物经济学第四版[M].中国医药科技出版社,2019.
[2] 胡善联.四问创新药医保谈判价格“红线” 中国ICER阈值3个人均GDP?[N]. 医药经济报,2021-10-07(A04).
[3] 郑培根. 决策方法及其应用[M].江西科学技术出版社, 1997.
[4] 冯尚友. 多目标决策理论方法与应用[J].华中理工大学出版社,1990.
[5] Lakdawalla DN, etal. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Repor[J].Value Health,2018 Feb;21(2):131-139.
[6] 孙利华,陶海英,刘琰.对我国药品管理目标的思考[J].中国药房,2007(28):2165-2167.